Cardiometabolic DiseasesNCT07675928
Qatar Cardiometabolic Cohort
An observational study of Cardiometabolic Diseases, run by Weill Cornell Medical College in Qatar at 1 site in Qatar.
Trial summary
Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Cardiometabolic Diseases
- How many people
- 3,000 participants
- Where
- 1 siteQatar
- Study dates
- 1 Dec 2026to 30 Dec 2036
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be recruited at Hamad Medical Corporation
Who may be able to join
- Qataris
- Long-term residents (≥10 years of residence in Qatar) who are not planning to leave Qatar voluntarily within the next 5 years.
- Age ≥40 years.
- English or Arabic speaker.
- Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.
- ASCVD:
Show all 30Show fewer
- ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.
- i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:
- Coronary Artery Disease (CAD)
- Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI))
- Stable or unstable angina with angiographic stenosis ≥50%
- History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG))
- Cerebrovascular Disease
- •Ischemic stroke or transient ischemic attack (TIA)
- Symptomatic carotid artery stenosis ≥50% or prior carotid intervention
- Peripheral Arterial Disease (PAD) •Intermittent claudication with objective evidence of arterial obstruction
- •Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI <0.9
- Aortic Atherosclerotic Disease •Aortic aneurysm (abdominal or thoracic) of atherosclerotic origin ii.Unequivocally Documented ASCVD on Imaging:
- Coronary artery calcium (CAC) score >100 Agatston units or >75th percentile for age and sex b. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery c. Carotid ultrasound or angiography showing plaque or ≥50% stenosis d. Lower-limb CT/MR/Doppler angiography showing atherosclerotic plaque or stenosis ≥50%
- Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines): •10-year fatal/non-fatal CVD risk ≥7.5% using SCORE2 (ages 40-49),≥10% using SCORE2 (ages 50-69), or ≥15% using SCORE2-OP (age≥70 years)
- •Severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²; or eGFR 30-44 mL/min/1.73 m² and UACR >30 mg/g.
- ii.In diabetic patients (ESC 2023 Diabetes \& CVD Guidelines):
- •10-year fatal/non-fatal CVD risk ≥20% using SCORE2-Diabetes (ages 40-69),or ≥15% using SCORE2-OP (age ≥70),since SCORE2-Diabetes is not validated beyond age 69. Severe target organ damage:
- •Severe target organ damage:
- <!-- -->
- eGFR <45 mL/min/1.73m² (regardless of albuminuria)
- eGFR 45-59 mL/min/1.73m² with microalbuminuria (UACR 30-300 mg/g)
- Proteinuria (UACR >300 mg/g)
- Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy).
- 3.Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy)
Who cannot join
- Type 1 diabetes or monogenic diabetes (e.g., MODY).
- Pregnancy (self-reported).
- Active cancer, under medical or radiation therapy or terminal, or cancer in remission < 1 year.
- Chronic immune or chronic infectious diseases.
- End stage renal disease (ESRD) (estimated glomerular filtration rate <15 mL/min/1.73m²).
- Prisoners.
- Inability or unwillingness to provide informed consent, including language barriers.
- Mental incapacity.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Qatar1 site
Hamad Medical Corporation
Doha
Jassim Al Suwaidi, MD, +974 4439 5354, jalsuwaidi@hamad.qa
About this study
Official title: Qatar Cardiometabolic Cohort (QCMC)
Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.
Read the detailed description
Qatar, along with other Gulf Cooperation Council (GCC) countries, experiences one of the highest rates of diabetes, obesity, and cardiovascular risk factors. However, the impact of those risk factors on cardiac diseases, in particular atherosclerotic cardiovascular disease (ASCVD), is not well studied. Further, the incidence of mortality in participants with diabetes and high cardiovascular risk is not known.
We will conduct a prospective, longitudinal, observational cohort that investigates the natural history of cardiometabolic diseases in citizens and long-term residents in Qatar: the Qatar Cardiometabolic Cohort (QCMC). The cohort will examine the prevalence, risk factors, and characterization of cardiometabolic patients, as well as the incidence of mortality and ASCVD events.
- Conditions
- Cardiometabolic Diseases
- Keywords
- cardiometabolic diseases, atherosclerotic cardiovascular disease, diabetes
- Medical subject headings
- Atherosclerosis, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Groupe 1: Controls (C) | Non-diabetic patients, defined as having an HbA1c < 5.7%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk | |
| Groupe 2: Cases-1 (pre-D) | Patients with pre-diabetes, defined as having an HbA1c between 5.7≤HbA1C ≤6.4, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk | |
| Groupe 3: Cases-2 (T2D) | Patients with type 2 diabetes, defined as having an HbA1c ≥ 6.5%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes)
To compare the incidence of major adverse cardiovascular events (3-point MACE:
cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) across three groups of adults with established ASCVD or very high cardiovascular risk: non-diabetes, pre-diabetes, and type 2 diabetes.
Measured: Baseline, Year 2, and Year 5
Secondary outcomes (21)
Change in body mass index (BMI)
Change in BMI (kg/m²) from baseline (Year 0) to Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5
Change in waist-to-hip ratio
Change in waist-to-hip ratio from baseline (Year 0) at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5
Change in fasting glucose
Change in fasting glucose from baseline (Year 0) at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5.
Change in glycated hemoglobin (HbA1c)
Change in HbA1c (%) from baseline (Year 0) at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5
Change in lipid profile parameters
Parameters include total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Changes from baseline will be assessed at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5.
Change in systolic and diastolic blood pressure
Change in systolic and diastolic blood pressure (mmHg) from baseline (Year 0) at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5
Electrocardiogram (ECG) - Heart Rate
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline in heart rate -beats per minute will be assessed at Year 2 and Year 5."
Measured: Baseline, Year 2, and Year 5.
ECG - PR interval
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline will be assessed in the PR interval (ms-milli second) at Year 2 and Year 5."
Measured: Baseline, Year 2, and Year 5.
ECG - QTc interval
ECGs will be evaluated for clinically significant abnormalities in the QTc interval in ms-milliseconds. Changes from baseline will be assessed at Year 2 and Year 5."
Measured: Baseline, Year 2, and Year 5
ECG- QRS Duration
ECGs will be evaluated for clinically significant abnormalities in the QRS duration (ms-milli second). Changes from baseline will be assessed at Year 2 and Year 5.
Measured: Baseline, Year 2, and Year 5.
Liver Stiffness Measurement
Change in liver stiffness (kPa) assessed by Fibroscan from baseline (Year 0) at Year 2 and Year 5
Measured: Baseline, Year 2, and Year 5
Controlled Attenuation Parameter
Quantitative measure obtained by FibroScan (transient elastography) that assesses hepatic steatosis (liver fat content)- Unit: decibels per meter (dB/m) by measuring ultrasound attenuation in the liver.
Measured: Baseline, Year 2, and Year 5
Left Ventricular Ejection Fraction - LVEF
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular ejection fraction (LVEF, %).
Measured: Baseline, Year 2, and Year 5.
Left Ventricular Mass Index
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular mass index unit- (g/m²).
Measured: Baseline, Year 2, and Year 5.
E/e' Ratio
Ratio of mitral inflow velocity to mitral annular tissue velocity; estimates left ventricular filling pressures and diastolic dysfunction severity assessed by Transthoracic echocardiography.
Measured: Baseline, Year 2, and Year 5.
E/A Ratio
Ratio of early (E) to late (A) mitral inflow velocities; used to assess left ventricular diastolic filling pattern to be assessed by Transthoracic echocardiography.
Measured: Baseline, Year 2, and Year 5.
Pulmonary Artery Systolic Pressure - PASP
Estimated pressure in the pulmonary artery derived from tricuspid regurgitation velocity; reflects pulmonary hypertension and right heart load will be measured using Transthoracic echocardiography in mmHg.
Measured: Baseline, Year 2, and Year 5.
Tricuspid Annular Plane Systolic Excursion - TAPSE
Measure longitudinal movement of the tricuspid annulus, indicator of right ventricular systolic function in Transthoracic echocardiography unit mm.
Measured: Baseline, Year 2, and Year 5.
Incidence of major adverse cardiovascular events (4-point MACE)
4-point MACE will be defined as a composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, and hospitalization for unstable angina
Measured: Baseline (Year 0), Year 2, and Year 5
Incidence of new-onset cardiac diseases and cardiovascular revascularization procedures
New-onset cardiac diseases will include heart failure, atrial fibrillation or other arrhythmias, and valvular heart disease. Cardiovascular revascularization procedures will include coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI/PTCA), carotid angioplasty, carotid endarterectomy, and lower limb revascularization.
Measured: Baseline (Year 0), Year 2, Year 5
Incidence of new non-cardiac diseases requiring hospitalization
This outcome includes the development of any new non-cardiac medical condition requiring hospital admission, excluding cardiovascular causes. Hospitalizations will be categorized by system (e.g., infectious, respiratory, renal, gastrointestinal, or other medical causes).
Measured: Baseline (Year 0), Year 2, and Year 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2026
- Study start1 Dec 2026 (estimated)
- Primary completion30 Dec 2036 (estimated)
- Study completion30 Dec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiometabolic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Weill Cornell Medical College in Qatar
- Sponsor type
- University, hospital or other
- Collaborators
- Hamad Medical Corporation
- Responsible party
- Sponsor
- Investigators
- Charbel Abi Khalil, MD,PhD, Principal investigator, Weill Cornell Medicine-Qatar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07675928
- Sponsor's protocol ID
- 26-00001
- Status last verified
- Oct 2026
- First submitted
- 6 Apr 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: ongoing discussion with the sponsor
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Qatar Cardiometabolic Cohort (QCMC)
- ClinicalTrials.gov ID
- NCT07675928
- Acronym / sponsor ID
- 26-00001
- Conditions
- Cardiometabolic Diseases
- Keywords
- cardiometabolic diseases, atherosclerotic cardiovascular disease, diabetes
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Weill Cornell Medical College in QatarUniversity, hospital or other
- Collaborators
- Hamad Medical Corporation
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 30 Dec 2036 (estimated)
- Study completion
- 30 Dec 2036 (estimated)
- First posted
- 30 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.
Detailed description
Qatar, along with other Gulf Cooperation Council (GCC) countries, experiences one of the highest rates of diabetes, obesity, and cardiovascular risk factors. However, the impact of those risk factors on cardiac diseases, in particular atherosclerotic cardiovascular disease (ASCVD), is not well studied. Further, the incidence of mortality in participants with diabetes and high cardiovascular risk is not known.
We will conduct a prospective, longitudinal, observational cohort that investigates the natural history of cardiometabolic diseases in citizens and long-term residents in Qatar: the Qatar Cardiometabolic Cohort (QCMC). The cohort will examine the prevalence, risk factors, and characterization of cardiometabolic patients, as well as the incidence of mortality and ASCVD events.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Groupe 1: Controls (C) | – | –Non-diabetic patients, defined as having an HbA1c < 5.7%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk |
| Groupe 2: Cases-1 (pre-D) | – | –Patients with pre-diabetes, defined as having an HbA1c between 5.7≤HbA1C ≤6.4, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk |
| Groupe 3: Cases-2 (T2D) | – | –Patients with type 2 diabetes, defined as having an HbA1c ≥ 6.5%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be recruited at Hamad Medical Corporation
Key inclusion criteria (30 listed)
- Qataris
- Long-term residents (≥10 years of residence in Qatar) who are not planning to leave Qatar voluntarily within the next 5 years.
- Age ≥40 years.
- English or Arabic speaker.
- Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.
Key exclusion criteria (8 listed)
- Type 1 diabetes or monogenic diabetes (e.g., MODY).
- Pregnancy (self-reported).
- Active cancer, under medical or radiation therapy or terminal, or cancer in remission < 1 year.
- Chronic immune or chronic infectious diseases.
- End stage renal disease (ESRD) (estimated glomerular filtration rate <15 mL/min/1.73m²).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes)
Time frame: Baseline, Year 2, and Year 5
To compare the incidence of major adverse cardiovascular events (3-point MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) across three groups of adults with established ASCVD or very high cardiovascular risk: non-diabetes, pre-diabetes, and type 2 diabetes.
21 secondary outcomes
Change in body mass index (BMI)
Time frame: Baseline, Year 2, and Year 5
Change in waist-to-hip ratio
Time frame: Baseline, Year 2, and Year 5
Change in fasting glucose
Time frame: Baseline, Year 2, and Year 5.
Change in glycated hemoglobin (HbA1c)
Time frame: Baseline, Year 2, and Year 5
Change in lipid profile parameters
Time frame: Baseline, Year 2, and Year 5.
Change in systolic and diastolic blood pressure
Time frame: Baseline, Year 2, and Year 5
Electrocardiogram (ECG) - Heart Rate
Time frame: Baseline, Year 2, and Year 5.
ECG - PR interval
Time frame: Baseline, Year 2, and Year 5.
ECG - QTc interval
Time frame: Baseline, Year 2, and Year 5
ECG- QRS Duration
Time frame: Baseline, Year 2, and Year 5.
Liver Stiffness Measurement
Time frame: Baseline, Year 2, and Year 5
Controlled Attenuation Parameter
Time frame: Baseline, Year 2, and Year 5
Left Ventricular Ejection Fraction - LVEF
Time frame: Baseline, Year 2, and Year 5.
Left Ventricular Mass Index
Time frame: Baseline, Year 2, and Year 5.
E/e' Ratio
Time frame: Baseline, Year 2, and Year 5.
E/A Ratio
Time frame: Baseline, Year 2, and Year 5.
Pulmonary Artery Systolic Pressure - PASP
Time frame: Baseline, Year 2, and Year 5.
Tricuspid Annular Plane Systolic Excursion - TAPSE
Time frame: Baseline, Year 2, and Year 5.
Incidence of major adverse cardiovascular events (4-point MACE)
Time frame: Baseline (Year 0), Year 2, and Year 5
Incidence of new-onset cardiac diseases and cardiovascular revascularization procedures
Time frame: Baseline (Year 0), Year 2, Year 5
Incidence of new non-cardiac diseases requiring hospitalization
Time frame: Baseline (Year 0), Year 2, and Year 5
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: Undecided. ongoing discussion with the sponsor
Related trials for Cardiometabolic Diseases
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health
Recruiting
Combating Alzheimer's Through Sleep and Exercise
Dementia, Mild Cognitive Impairment (MCI)
Recruiting
Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health
Heart Diseases
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
Not yet recruiting
Effects of Increased Water Intake on Hormonal Response, Hydration Status, and Physical Function in Low-drinking Older Adults
Dehydrated, Water-Electrolyte Imbalance, Malnutrition, Dehydration (Physiology)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charbel Abi Khalil, MD,PhD principal investigator
Weill Cornell Medicine-Qatar
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiometabolic Diseases, run by Weill Cornell Medical College in Qatar at 1 site in Qatar.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 30 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Qatar. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charbel Abi khalil, MD,PhD (+974 4492 8484, cha2022@qatar-med.cornell.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes) (time frame: Baseline, Year 2, and Year 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.